2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenWhy are so many people so heavily invested in individual stocks, and in a seemingly impatient, hopeful, gambler-like way? I believe there is much truth in what Buffet once said when he was asked why nobody does as he does: Nobody wants go get rich slowly. As I see it, individual stocks are largely gambling. With very few exceptions (perhaps if one is an insider) it is almost impossible to know what is a value trap. Nearly impossible to come up with a correct assessment of a company's valuation and future prospects. At least nearly impossible to consistently make above-average smart analyses of that kind. I myself have been such a clown almost my entire life. I have been a terrible investor except for maybe the last few years. Regardless, as I see it, it is largely best to have broad index funds. Perhaps it's strange why I'm writing this here on the Novo-thread. This is because Novo is currently my only individual stock (as a rule, I haven't had any individual stocks; Novo constitutes 7% of the portfolio, bought a few months ago, partly bought because my wife likes healthcare and I think healthcare-ETF seems a bit expensive at the moment). The worst thing about owning Novo is the blue dots on the Nordnet-app. Endlessw notifications about the, to put it mildly, uninteresting posts written about the stock. But they become fewer along the way, I think I have muted approx. 30 Novo-"investors" in the last few days after discovering that one can clean up that way. Much needed.
·18 min sitten
·2 t sittenThe Wegovy pill is currently winning the pill market. SNAC technology protects the liver and avoids interactions with other medicines. Foundayo is the 'liver-killer' pill — people avoid it because no one wants to risk losing their liver. It is very likely that the approval process in Europe for Foundayo will be extended or require additional documentation. The reason is that the US health authorities (FDA) have flagged "unexpected" signals regarding liver toxicity and require the manufacturer Eli Lilly to monitor and submit additional safety data from clinical studies. Novo has the most effective pill with the fewest side effects. People don't want to inject themselves like junkies. Everyone wants a pill, and the company with the most effective pill wins the obesity market.- ·3 t sittenMany Danes have probably now understood why mark-to-market taxation is called "the tax from hell". Those Danes who have opened an investment savings account and invested in Novo, have paid 17% mark-to-market tax on an unrealized capital gain that has disappeared, and if they close their investment savings account, they will realize a capital loss that is lost for tax purposes.·2 t sittenThere is probably no reason to close the account if one has an unused tax deduction. Then one can invest in some ETFs which in the long term yield a profit. If you invest in shares in a company, they are also mark-to-market taxed, just like the PAL tax on the pension scheme.
·3 t sittenActive Ingredient: The raw semaglutide required for a month's treatment costs an estimated $0.29 to $1.10.Delivery Device: The disposable, pre-filled injector pens used for Wegovy generally cost between $0.30 and $2.50 per device.Final Assembly: Adding in other chemical ingredients and "fill-finish" processes brings the total conceptual cost-based price to around $0.89 to $4.73 per month.The cost for a user today is 40k per year. Or around 3000 usd. This is clearly more than the large masses can or are willing to pay. But with production costs at this level, it's really just a matter of increasing production enough, and then there will be an enormous market available.
·4 t sittenWhat we see in the latest prescription curves in the USA looks like a failure for Foundayo and a huge success for Wegovy. As previously stated, only 1/4 of newly developed medicine becomes a success.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenWhy are so many people so heavily invested in individual stocks, and in a seemingly impatient, hopeful, gambler-like way? I believe there is much truth in what Buffet once said when he was asked why nobody does as he does: Nobody wants go get rich slowly. As I see it, individual stocks are largely gambling. With very few exceptions (perhaps if one is an insider) it is almost impossible to know what is a value trap. Nearly impossible to come up with a correct assessment of a company's valuation and future prospects. At least nearly impossible to consistently make above-average smart analyses of that kind. I myself have been such a clown almost my entire life. I have been a terrible investor except for maybe the last few years. Regardless, as I see it, it is largely best to have broad index funds. Perhaps it's strange why I'm writing this here on the Novo-thread. This is because Novo is currently my only individual stock (as a rule, I haven't had any individual stocks; Novo constitutes 7% of the portfolio, bought a few months ago, partly bought because my wife likes healthcare and I think healthcare-ETF seems a bit expensive at the moment). The worst thing about owning Novo is the blue dots on the Nordnet-app. Endlessw notifications about the, to put it mildly, uninteresting posts written about the stock. But they become fewer along the way, I think I have muted approx. 30 Novo-"investors" in the last few days after discovering that one can clean up that way. Much needed.·18 min sitten
- ·2 t sittenThe Wegovy pill is currently winning the pill market. SNAC technology protects the liver and avoids interactions with other medicines. Foundayo is the 'liver-killer' pill — people avoid it because no one wants to risk losing their liver. It is very likely that the approval process in Europe for Foundayo will be extended or require additional documentation. The reason is that the US health authorities (FDA) have flagged "unexpected" signals regarding liver toxicity and require the manufacturer Eli Lilly to monitor and submit additional safety data from clinical studies. Novo has the most effective pill with the fewest side effects. People don't want to inject themselves like junkies. Everyone wants a pill, and the company with the most effective pill wins the obesity market.
- ·3 t sittenMany Danes have probably now understood why mark-to-market taxation is called "the tax from hell". Those Danes who have opened an investment savings account and invested in Novo, have paid 17% mark-to-market tax on an unrealized capital gain that has disappeared, and if they close their investment savings account, they will realize a capital loss that is lost for tax purposes.·2 t sittenThere is probably no reason to close the account if one has an unused tax deduction. Then one can invest in some ETFs which in the long term yield a profit. If you invest in shares in a company, they are also mark-to-market taxed, just like the PAL tax on the pension scheme.
- ·3 t sittenActive Ingredient: The raw semaglutide required for a month's treatment costs an estimated $0.29 to $1.10.Delivery Device: The disposable, pre-filled injector pens used for Wegovy generally cost between $0.30 and $2.50 per device.Final Assembly: Adding in other chemical ingredients and "fill-finish" processes brings the total conceptual cost-based price to around $0.89 to $4.73 per month.The cost for a user today is 40k per year. Or around 3000 usd. This is clearly more than the large masses can or are willing to pay. But with production costs at this level, it's really just a matter of increasing production enough, and then there will be an enormous market available.
- ·4 t sittenWhat we see in the latest prescription curves in the USA looks like a failure for Foundayo and a huge success for Wegovy. As previously stated, only 1/4 of newly developed medicine becomes a success.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenWhy are so many people so heavily invested in individual stocks, and in a seemingly impatient, hopeful, gambler-like way? I believe there is much truth in what Buffet once said when he was asked why nobody does as he does: Nobody wants go get rich slowly. As I see it, individual stocks are largely gambling. With very few exceptions (perhaps if one is an insider) it is almost impossible to know what is a value trap. Nearly impossible to come up with a correct assessment of a company's valuation and future prospects. At least nearly impossible to consistently make above-average smart analyses of that kind. I myself have been such a clown almost my entire life. I have been a terrible investor except for maybe the last few years. Regardless, as I see it, it is largely best to have broad index funds. Perhaps it's strange why I'm writing this here on the Novo-thread. This is because Novo is currently my only individual stock (as a rule, I haven't had any individual stocks; Novo constitutes 7% of the portfolio, bought a few months ago, partly bought because my wife likes healthcare and I think healthcare-ETF seems a bit expensive at the moment). The worst thing about owning Novo is the blue dots on the Nordnet-app. Endlessw notifications about the, to put it mildly, uninteresting posts written about the stock. But they become fewer along the way, I think I have muted approx. 30 Novo-"investors" in the last few days after discovering that one can clean up that way. Much needed.·18 min sitten
- ·2 t sittenThe Wegovy pill is currently winning the pill market. SNAC technology protects the liver and avoids interactions with other medicines. Foundayo is the 'liver-killer' pill — people avoid it because no one wants to risk losing their liver. It is very likely that the approval process in Europe for Foundayo will be extended or require additional documentation. The reason is that the US health authorities (FDA) have flagged "unexpected" signals regarding liver toxicity and require the manufacturer Eli Lilly to monitor and submit additional safety data from clinical studies. Novo has the most effective pill with the fewest side effects. People don't want to inject themselves like junkies. Everyone wants a pill, and the company with the most effective pill wins the obesity market.
- ·3 t sittenMany Danes have probably now understood why mark-to-market taxation is called "the tax from hell". Those Danes who have opened an investment savings account and invested in Novo, have paid 17% mark-to-market tax on an unrealized capital gain that has disappeared, and if they close their investment savings account, they will realize a capital loss that is lost for tax purposes.·2 t sittenThere is probably no reason to close the account if one has an unused tax deduction. Then one can invest in some ETFs which in the long term yield a profit. If you invest in shares in a company, they are also mark-to-market taxed, just like the PAL tax on the pension scheme.
- ·3 t sittenActive Ingredient: The raw semaglutide required for a month's treatment costs an estimated $0.29 to $1.10.Delivery Device: The disposable, pre-filled injector pens used for Wegovy generally cost between $0.30 and $2.50 per device.Final Assembly: Adding in other chemical ingredients and "fill-finish" processes brings the total conceptual cost-based price to around $0.89 to $4.73 per month.The cost for a user today is 40k per year. Or around 3000 usd. This is clearly more than the large masses can or are willing to pay. But with production costs at this level, it's really just a matter of increasing production enough, and then there will be an enormous market available.
- ·4 t sittenWhat we see in the latest prescription curves in the USA looks like a failure for Foundayo and a huge success for Wegovy. As previously stated, only 1/4 of newly developed medicine becomes a success.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt